You are here

Our science / Clinical Trials / Find a Trial / NCT03850483

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

Back to Search Print Save as PDF Bookmark Trial

NCT03850483

Last updated on January 23, 2020
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Bayside Dermatology Center
Bayside, New York, 11360 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- plaque psoriasis for 6 months

- PGA score mild or moderate

- body surface area (BSA) 2-15%

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- other skin conditions that would interfere with the evaluation of psoriasis

- history of herpes zoster or simplex

- Infected with Mycobacterium tuberculosis

NCT03850483
Pfizer
Recruiting
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Psoriasis
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
NCT03850483
All Genders
18+
Years
Multiple Sites
Psoriasis
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
NCT03895372
All Genders
18+
Years
Multiple Sites
Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
NCT03885089
All Genders
0+
Years
Tokyo,
Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Plaque Psoriasis
A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
NCT02486302
All Genders
18+
Years
Multiple Sites
Descriptive Information
Brief Title  ICMJE Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
Official Title  ICMJE A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY TO ASSESS EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
Brief Summary This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and approximately 4 week follow up period. Approximately 240 participants are planned to be randomized into the study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Psoriasis
Intervention  ICMJE
  • Drug: PF-06700841
    PF-06700841 topical cream
  • Drug: Vehicle (Placebo)
    Vehicle topical cream
Study Arms  ICMJE
  • Placebo Comparator: Vehicle cream QD
    Vehicle cream applied once daily (QD)
    Intervention: Drug: Vehicle (Placebo)
  • Experimental: PF-06700841 0.1% cream QD
    PF-06700841 0.1% cream applied once daily (QD)
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 0.3% cream QD
    PF-06700841 0.3% cream applied once daily (QD)
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 1% cream QD
    PF-06700841 1% cream applied once daily (QD)
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 3% cream QD
    PF-06700841 3% cream applied once daily (QD)
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 0.3% cream BID
    PF-06700841 0.3% cream applied twice daily (BID)
    Intervention: Drug: PF-06700841
  • Experimental: PF-06700841 1% cream BID
    PF-06700841 1% cream applied twice daily (BID)
    Intervention: Drug: PF-06700841
  • Placebo Comparator: Vehicle cream BID
    Vehicle cream applied twice daily (BID)
    Intervention: Drug: Vehicle (Placebo)
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 20, 2019) 		240
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 13, 2020
Estimated Primary Completion Date May 13, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • plaque psoriasis for 6 months
  • PGA score mild or moderate
  • body surface area (BSA) 2-15%

Exclusion Criteria:

  • other skin conditions that would interfere with the evaluation of psoriasis
  • history of herpes zoster or simplex
  • Infected with Mycobacterium tuberculosis
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Listed Location Countries  ICMJE Australia,   Bulgaria,   Canada,   Denmark,   Germany,   Hungary,   Japan,   Latvia,   Poland,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03850483
Other Study ID Numbers  ICMJE B7931023
2018-003051-38 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date January 2020

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now